NEW YORK, March 7, 2017 /PRNewswire/ --
In today's pre-market research, Stock-Callers.com draws investors' attentionto these Medical Laboratories and Research equities: PAREXEL International Corp. (NASDAQ: PRXL), Novadaq Technologies Inc. (NASDAQ: NVDQ), Charles River Laboratories International Inc. (NYSE: CRL), and PRA Health Sciences Inc. (NASDAQ: PRAH). These companies
Waltham, Massachusetts headquartered PAREXEL International Corp.'s stock finished Monday's session 0.81% lower at $64.76 with a total trading volume of 675,512 shares. The Company's shares have advanced 1.30% in the past month and 10.63% in the previous three months. The stock is trading 0.20% below its 200-day moving average. Additionally, shares of PAREXEL International, which provides clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology products and services for pharmaceutical, biotechnology, and medical device industries worldwide, have a Relative Strength Index (RSI) of 43.10.
On February 28th, 2017, PAREXEL announced the appointment of Simon Harford as Senior Vice President and Chief Financial Officer effective June 01st, 2017. He will serve on PAREXEL's Business Review Committee, and assist in developing and implementing PAREXEL's strategic objectives. Mr. Harford will be based at the Company's corporate headquarters in Waltham, Massachusetts. Access our complete research report on PRXL for free at:
On Monday, shares in Mississauga, Canada headquartered Novadaq Technologies Inc. recorded a trading volume of 324,005 shares. The stock ended the session 1.82% lower at $7.56. The Company's shares have advanced 18.31% in the last one month and 6.63% on an YTD basis. The stock is trading above its 50-day moving average by 9.41%. Moreover, shares of Novadaq Technologies, which develops, manufactures, and markets fluorescence imaging products for use by surgeons in the operating room and other clinical settings in the US and internationally, have an RSI of 61.20.
On February 21st, 2017, LifeNet Health announced that Global health services Company Cigna (CI) will cover Dermacell® for breast reconstruction surgery and Dermacell AWM® for diabetic foot ulcers. Dermacell is an advanced acellular dermal matrix developed by LifeNet Health and distributed exclusively by Novadaq Technologies. With this decision, more than 15 million Cigna's members throughout Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Maryland, Missouri, North and South Carolina, Tennessee, Texas, and Virginia will have coverage for Dermacell and Dermacell AWM. The complimentary research report on NVDQ can be downloaded at:
Charles River Laboratories
Wilmington, Massachusetts headquartered Charles River Laboratories International Inc.'s shares closed the day 0.61% lower at $87.50. The stock recorded a trading volume of 349,444 shares. The Company's shares have gained 6.89% in the last month, 24.96% over the previous three months, and 14.84% on an YTD basis. The stock is trading 7.00% and 7.78% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Charles River Laboratories International, which provides drug discovery and development services worldwide, have an RSI of 59.96.
On February 14th, 2017, Charles River Laboratories announced that revenue from continuing operations was $466.8 million for Q4 2016, an increase of 31.9% from $353.9 million in Q4 2015. On a GAAP basis, net income from continuing operations attributable to common shareholders was $44.7 million for Q4 2016, an increase of 36.4% from $32.8 million for Q4 2015. Charles Rivers' Q4 2016 diluted earnings per share on a GAAP basis were $0.93, an increase of 34.8% from $0.69 for Q4 2015. Register for free on Stock-Callers.com and get access to the latest PDF format report on CRL at:
PRA Health Sciences
Shares in Raleigh, North Carolina headquartered PRA Health Sciences Inc. finished 0.30% lower at $58.92. The stock recorded a trading volume of 457,849 shares. The Company's shares have advanced 1.10% in the last one month, 13.31% in the previous three months, and 6.89% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 2.50% and 13.03%, respectively. Furthermore, shares of PRA Health Sciences, which provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide, have an RSI of 49.16.
On February 22nd, 2017, PRA Health Sciences reported that service revenue was $413.6 million for Q4 2016, which represents growth of 14.2% on a y-o-y basis. The Company's net new business for Q4 2016 was $587.3 million, representing a net book-to-bill ratio of 1.42 for the period. PRA Health's GAAP net income was $14.0 million for Q4 2016 compared to GAAP net income of $28.5 million for Q4 2015.
On February 27th, 2017, research firm Avondale upgraded the Company's stock rating from 'Market Underperform' to 'Market Perform'. Download your free research report on PRAH at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Acute coronary syndrome (ACS) is a sudden, acute life-threatening condition caused by a dramatic ...
Sclerotherapy is a procedure used to treat spider veins, varicose veins and hemorrhoids by directly ...
HELLP syndrome is a rare but serious complication that affects pregnant women. If detected on time, ...View All